David Meeker, MD
Rhythm Pharmaceuticals, Inc.
19
0
15
N/A
0
12
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (19)
Showing 10 of 19 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
David Crowley, MD
KGK Science Inc.
Shared therapeutic areas:
Jack A Yanovski, M.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Murad Alam, MD
Northwestern University
Shared therapeutic areas:
David s Ludwig, MD, PhD
Boston Children's Hospital
Shared therapeutic areas:
Britt Burton-Freeman, ph.D
Illinois Institute of Technology
Shared therapeutic areas:
Shirley Wang, PhD, ScM
Brigham and Women's Hospital
Shared therapeutic areas:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Waqar ahmed awan, Phd
Riphah International University
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (19)
Showing 19 of 19 trials
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Open-Label Extension Study of Setmelanotide
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
Open-Label Study of Setmelanotide in Hypothalamic Obesity
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Long Term Extension Trial of Setmelanotide
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
All 19 trials loaded